Imphal, Feb 18: The Directorate of AYUSH, Manipur has issued a stern warning against the manufacture and sale of AYUSH and herbal products without valid licences, signalling a crackdown amid rising concerns over unregulated goods and misleading advertisements in the alternative medicine sector.
Speaking at a press conference, Director Dr Akoijam Lokendra Singh made it clear that authorities will adopt a zero-tolerance approach toward violations of licensing requirements and promotional guidelines. He stated that any individual or entity found producing or selling AYUSH or herbal medicines without approval from the competent authority will face strict legal consequences.
Dr Singh noted that both the Supreme Court and the Ministry of AYUSH have instructed states to rigorously enforce regulations governing the production and advertisement of AYUSH and herbal products. According to him, these measures are aimed at curbing misleading claims and safeguarding the public from potential health risks.
He highlighted that deceptive advertisements related to AYUSH medicines, cosmetic items and ophthalmic preparations are punishable under the Drugs and Cosmetics Act, 1940 and its associated rules. Violations of advertising norms can result in imprisonment of up to six months, a fine, or both, while repeat offences may attract up to one year of imprisonment or a fine, or both.
The Director further disclosed that, to date, no licences have been granted to any company or manufacturer for producing AYUSH products in Manipur. Although several entrepreneurs have applied, none have met the prescribed regulatory standards required for approval. Under the Drugs and Cosmetics Act, 1940, prior licensing is mandatory for manufacturing AYUSH or herbal medicines or establishing a pharmacy. Non-compliance can lead to one year of imprisonment or a fine of ₹20,000, or both, with repeat violations carrying penalties of up to two years’ imprisonment or a fine of ₹50,000, or both.
Dr Singh also warned against the circulation of misleading information about AYUSH or herbal products in media reports and on social media platforms. While the Directorate has not yet received formal complaints, he cautioned that any violations detected after the announcement would prompt immediate legal action. He urged individuals engaged in such activities to cease immediately and remove any misleading content.
Appealing to the public, Dr Singh advised consumers to verify licences before purchasing AYUSH or herbal medicines and to ensure compliance with all applicable legal provisions, reinforcing the Directorate’s commitment to public health and regulatory oversight.
